Theratechnologies
Yahoo Finance • 5 days ago
Theratechnologies Inc (THTX) Q4 2024 Earnings Call Highlights: Strong EBITDA Turnaround and ...
Adjusted EBITDA: $20 million for fiscal year 2024, compared to minus $3 million a year ago. Net Sales: $25 million for Q4 2024, a 6.6% growth versus the same quarter last year. EGRIFTA SV Sales: $17.7 million in Q4 2024, a 4% increase year... Full story
Yahoo Finance • 6 days ago
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024
Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding latest guidance of $17-19 million Achieved record quarterly revenue of $25 million and annual revenue of $85.9 million New credit f... Full story
Yahoo Finance • 18 days ago
Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
MONTREAL, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have... Full story
Yahoo Finance • 19 days ago
Theratechnologies Resumes Distribution of EGRIFTA SV®
MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have... Full story
Yahoo Finance • last year
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
MONTREAL, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, tod... Full story
Yahoo Finance • last year
Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. Common shares priced at US$1.00 per... Full story
Yahoo Finance • last year
Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 25, 2023 (GLOBE NE... Full story
Yahoo Finance • last year
Theratechnologies Announces Operational Update
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 24, 2023 (GLOBE NE... Full story
Yahoo Finance • last year
Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
Data presented at AMCP Nexus 2023 highlight implications for U.S. payers based on cost-effectiveness and improved outcomes This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement d... Full story
Yahoo Finance • last year
Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon
- Revised the Minimum Liquidity Covenant for All Times Following October 31, 2023 to be Between US$15 Million and US$20 Million - Minimum Quarterly Revenue Covenant Replaced with Minimum Adjusted EBITDA Covenant - Deleted Prohibition Aga... Full story
Yahoo Finance • last year
Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
Significant reduction in INSTI-associated VAT accumulation with tesamorelin contrasts with VAT increase in patients taking placebo VAT accumulation observed after 12 months on INSTI-containing regimens, even in the absence of significant... Full story
Yahoo Finance • last year
Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 13, 2023 (GLOBE NE... Full story
Yahoo Finance • last year
Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Milestone for Company’s lead peptide-drug conjugate candidate follows FDA acceptance of protocol amendment for Phase 1 study on June 2, 2023 MONTREAL, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the... Full story
Yahoo Finance • last year
Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 04, 2023 (GLOBE NE... Full story
Yahoo Finance • last year
Theratechnologie reçoit la date cible d'approbation de janvier 2024 à la licence de produit biologique (sBLA) pour la formulation F8 de la tésamoréline
Le présent communiqué de presse constitue un « communiqué désigné » aux fins du supplément de prospectus de la Société daté du 16 décembre 2021 à son prospectus préalable de base simplifié daté du 14 décembre 2021. MONTRÉAL, 04 oct. 2023... Full story
Yahoo Finance • last year
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
Q3 2023 consolidated revenue of $20.9 million, adjusted EBITDA of $2.2 million sBLA for F8 formulation of tesamorelin submitted to FDA Agreement in principle on key amendments to loan facility with Marathon MONTREAL, Sept. 26, 2023 (GLO... Full story
Yahoo Finance • last year
Theratechnologies présente ses résultats financiers pour le troisième trimestre et les neuf premiers mois de l’exercice 2023 et fait le point sur ses activités commerciales
Revenus consolidés de 20,9 millions de dollars et BAIIA ajusté de 2,2 millions de dollars au troisième trimestre de 2023 Dépôt d’une sBLA relative à la formulation F8 de la tésamoréline auprès de la FDA Entente de principe visant des modif... Full story
Yahoo Finance • last year
Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility
- Removal of Minimum Liquidity Covenant of US$30 Million if F8 Formulation of Tesamorelin is Not Approved by the FDA by March 31, 2024 - Minimum Liquidity Covenant to Decrease Over Time to a Minimum of US$15 million from US$20 Million Bas... Full story
Yahoo Finance • last year
Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophy MONTREAL, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies... Full story
Yahoo Finance • last year
Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023
MONTREAL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, to... Full story
